

Agilent expands Altura portfolio with inert size exclusion and PLRP-S columns for biopharmaceutical analysis

July 9, 2026 | News

Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions



Agilent Technologies Inc. has announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.

The new SEC and PLRP-S columns support critical analytical workflows across a range of biopharmaceutical modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterisation, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterising antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity.

Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities.

The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA.